At the time of writing, Avalo Therapeutics Inc [AVTX] stock is trading at $11.88, up 4.85%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AVTX shares have gain 9.19% over the last week, with a monthly amount glided 33.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avalo Therapeutics Inc [NASDAQ: AVTX] stock has seen the most recent analyst activity on September 17, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $25 from $15. On August 15, 2025, Cantor Fitzgerald initiated with a Overweight rating. Stifel initiated its recommendation with a Buy and recommended $36 as its price target on March 25, 2025. Jefferies started tracking with a Buy rating for this stock on March 25, 2025, and assigned it a price target of $23. In a note dated February 28, 2025, Piper Sandler initiated an Overweight rating and provided a target price of $48 on this stock.
For the past year, the stock price of Avalo Therapeutics Inc fluctuated between $3.39 and $16.00. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Avalo Therapeutics Inc [NASDAQ: AVTX] shares were valued at $11.88 at the most recent close of the market. An investor can expect a potential return of 102.02% based on the average AVTX price forecast.
Analyzing the AVTX fundamentals
Gross Profit Margin for this corporation currently stands at 2.12% with Operating Profit Margin at -136.41%, Pretax Profit Margin comes in at -104.52%, and Net Profit Margin reading is -104.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.48 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Avalo Therapeutics Inc [NASDAQ:AVTX] has a current ratio of 12.44. Also, the Quick Ratio is 12.44, while the Cash Ratio stands at 4.57. Considering the valuation of this stock, the price to sales ratio is 355.12, the price to book ratio is 1.23.
Transactions by insiders
Recent insider trading involved Almenoff June Sherie, Director, that happened on Nov 13 ’24 when 500.0 shares were purchased. Director, Almenoff June Sherie completed a deal on Nov 12 ’24 to buy 500.0 shares.
